Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2

被引:0
|
作者
Ton, Minh That [1 ]
Ho, Tri Huynh Quang [2 ]
Nguyen, Viet Lan [3 ]
Pham, Hung Manh [3 ,4 ]
Van Hoang, Sy [3 ,4 ]
Vo, Nhan Thanh [5 ,6 ]
Nguyen, Thai Quoc [3 ]
Pham, Linh Tran [3 ]
Mai, Ton Duy [4 ,7 ,8 ]
Nguyen, Thang Huy [9 ,10 ]
机构
[1] Tam Duc Heart Hosp, Ho Chi Minh City, Vietnam
[2] Heart Inst, Surg Intens Care Unit, Ho Chi Minh City, Vietnam
[3] Bach Mai Hosp, Vietnam Heart Inst, Hanoi, Vietnam
[4] Hanoi Med Univ, Hanoi, Vietnam
[5] Cho Ray Hosp, Cardiovasc Dept, Ho Chi Minh City, Vietnam
[6] Vinmec Hosp, Cardiovasc Ctr, Ho Chi Minh City, Vietnam
[7] Bach Mai Hosp, Stroke Ctr, Hanoi, Vietnam
[8] VNU Univ Med & Pharm, Hanoi, Vietnam
[9] Peoples 115 Hosp, Cerebro Vasc Dis Dept, 527 Hanh St,Dist 10,Ward 12, Ho Chi Minh City 700000, Vietnam
[10] Pham Ngoc Thach Univ Med, Ho Chi Minh City, Vietnam
关键词
Atrial fibrillation; renal impairment; diabetes; coronary artery disease; elderly; bioprosthetic valve; DIABETES-MELLITUS; ELDERLY-PATIENTS; EMBOLISM TRIAL; RENAL-FUNCTION; ANTITHROMBOTIC THERAPY; RISK STRATIFICATION; WARFARIN; OUTCOMES; RIVAROXABAN; DABIGATRAN;
D O I
10.15420/ecr.2023.25
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations, including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1
    Ho, Tri Huynh Quang
    Ton, Minh That
    Nguyen, Viet Lan
    Pham, Hung Manh
    Van Hoang, Sy
    Vo, Nhan Thanh
    Nguyen, Thai Quoc
    Pham, Linh Tran
    Mai, Ton Duy
    Nguyen, Thang Huy
    EUROPEAN CARDIOLOGY REVIEW, 2023, 18
  • [2] What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?
    Shahid, Farhan
    Shantsila, Eduard
    Lip, Gregory Y. H.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 18 - 24
  • [3] Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly
    Ajam, Tarek
    Cumpian, Tabitha L.
    Tilkens, Blair L.
    Jahangir, Imaan A.
    Frost, Jared
    Ceretto, Cheryl
    Jahangir, Arshad
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (12) : 1309 - 1327
  • [4] Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
    Potpara, Tatjana S.
    Jokic, Vera
    Dagres, Nikolaos
    Larsen, Torben B.
    Lane, Deirdre A.
    Hindricks, Gerhard
    Lip, Gregory Y. H.
    CURRENT MEDICINAL CHEMISTRY, 2016, 23 (19) : 2055 - 2069
  • [5] Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
    Bisson, Arnaud
    Angoulvant, Denis
    Philippart, Raphael
    Clementy, Nicolas
    Babuty, Dominique
    Fauchier, Laurent
    ADVANCES IN THERAPY, 2017, 34 (06) : 1283 - 1290
  • [6] Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
    Plitt, Anna
    Ruff, Christian T.
    Giugliano, Robert P.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (05) : 1019 - +
  • [7] Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
    Turagam, Mohit K.
    Velagapudi, Poonam
    Flaker, Greg C.
    CLINICAL INTERVENTIONS IN AGING, 2015, 10 : 1431 - 1444
  • [8] Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients
    Wang, Stephen Y.
    Giugliano, Robert P.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 127 : 176 - 183
  • [10] Recurrent ischemic stroke in atrial fibrillation with non-vitamin K antagonist oral anticoagulation
    Woo, Ho Geol
    Chung, Inyoung
    Gwak, Dong Seok
    Kim, Baik Kyun
    Kim, Beom Joon
    Bae, Hee-Joon
    Han, Moon-Ku
    JOURNAL OF CLINICAL NEUROSCIENCE, 2019, 64 : 127 - 133